Disclaimer

The content provided on this website about psychedelic medicines is intended for informational and educational purposes only. It does not promote, encourage, or condone the use of illegal or controlled substances.

 Psychedelic-assisted therapy is an area of emerging clinical interest and research, but in many jurisdictions, the use of most psychedelic substances remains illegal except within approved medical or research contexts.  Cannabis is legal in Canada (where I live) and if you procure and provide your own can be used as a psychedelic-like substance in sessions.  Ketamine can be prescribed by a Dr. and used "off label" for a psychedelic experience in a regulated and licenced manner, and for some people, there are prescribing physicians who can apply to the Special Access Program (SAP) with Health Canada for access to some controlled psychedelic substances. 

The material presented in this website is not intended to substitute for professional medical, psychological, or legal advice. Individuals are strongly advised to consult with licensed healthcare providers and to comply with all laws and regulations applicable in their jurisdiction.

As part of a harm reduction approach, Kathy White has a PAT post-graduate certificate from VIU,   and is therefore qualified to offer therapeutic support prior to and following -  before and after support for psychedelic experiences. 

Such support is not intended to facilitate or guide or condone illegal substance use, but to help individuals minimize psychological risk, clarify their intentions, and process experiences that may arise.  Many clinical trials have shown that the evidence for using psychedelics as an effective treatment for many mental health or life situations* (see list and bibliography below for evidence).  Pre-experience preparation and post-experience integration are recognised as essential components for reducing harm, maximizing potential therapeutic benefits, and ensuring emotional and psychological safety.

By engaging with the content of this website, and or engaging with therapeutic services from Kathy White,  you acknowledge personal responsibility for your choices and agree to seek appropriate professional and legal guidance where necessary.

*Evidence Based Research on Effective Use of Psychedelics: 

• Treatment-resistant depression and major depression: Psilocybin-assisted therapy has shown meaningful reductions in depressive symptoms, including in people who did not improve with standard treatment.

• PTSD: MDMA-assisted psychotherapy has the strongest evidence base among psychedelic treatments for PTSD, with short-term improvements and some remission in trials.

• Substance use disorders: Evidence supports possible benefits for alcohol use disorder, tobacco addiction, and other substance-related problems.

• Anxiety and distress in serious illness: Psychedelics may reduce anxiety, depression, and existential distress in people facing life-threatening illness

Please note that all of the clinical trials and evidence that is currently available is subject to change as the number of trials for psilocybin alone worldwide in 2026 is estimated at well over 150. 

Bibliography

Here’s a list of research papers with active links, focused on psychedelic use in depression, PTSD, and related mental health conditions. 

• Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis — https://pubmed.ncbi.nlm.nih.gov/38574699/pubmed.ncbi.nlm.nih

• A Promise Without Panacea: Psychedelic-Assisted Therapies in Modern Psychiatry — https://pmc.ncbi.nlm.nih.gov/articles/PMC12945399/pmc.ncbi.nlm.nih

• Psychedelic therapeutics in psychiatric conditions — https://www.nature.com/articles/s41386-026-02335-znature

• Depression Symptoms — https://pmc.ncbi.nlm.nih.gov/articles/PMC12129050/pmc.ncbi.nlm.nih

• The development of psilocybin therapy for treatment-resistant depression — https://pmc.ncbi.nlm.nih.gov/articles/PMC10801413/pmc.ncbi.nlm.nih

• Reviewing the Potential of Psychedelics for the Treatment of PTSD — https://pmc.ncbi.nlm.nih.gov/articles/PMC7311646/pmc.ncbi.nlm.nih

• Psilocybin for Trauma-Related Disorders — https://pubmed.ncbi.nlm.nih.gov/35711024/pubmed.ncbi.nlm.nih

• The Efficacy of Psychedelic-Assisted Therapy in Managing Post-Traumatic Stress Disorder — https://pmc.ncbi.nlm.nih.gov/articles/PMC9710723/pmc.ncbi.nlm.nih

• Psilocybin-assisted massed cognitive processing therapy for chronic PTSD — https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0313741journals.plos

• Investigating the Therapeutic Effects of Psilocybin in treatment-resistant PTSD — https://clinicaltrials.gov/study/NCT05243329clinicaltrials